Evaluation of Onfi Conversion Therapy Replacing Clonazepam in Patients With Medically Refractory Epilepsy

Inclusion Criteria

• •Subject has a confirmed diagnosis of medically refractory epilepsy with or without secondary generalization for at least 12 months prior to the initial study visit.
• •Currently taking stable dosing regimen of clonazepam (0.5-4mg daily) for seizure control.
• •Takes at least one additional Anti-epileptic drug besides benzodiazepine.
• •Age 18-70 years, inclusive.
• •In opinion of investigator, can be safely treated with Onfi.
• •Minimum of 2 seizures, but no more than 24 complex partial or generalized seizures, during the 8-week baseline period prior to study entry.
• •Able to communicate effectively with study personnel and considered reliable, able, willing, and cooperative with regard to complying with protocol-defined requirements, including completion of study diary.